Cure My Disease

Don't miss your cure!

 Log in / Sign up

Real-World watch on ph+ leukemia treatments aims to uncover best paths to remission

NCT ID NCT07684131

Knowledge-focused Sponsor: Versailles Hospital Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jul 06, 2026 · Last updated Jul 07, 2026 · Updated 1 time

Summary

This study follows adults aged 18 and older who have a specific type of acute lymphoblastic leukemia (Ph+ ALL) and are receiving a combination of targeted drugs (BCR::ABL1 inhibitors) along with chemotherapy, steroids, or antibody therapy. Researchers will track how long patients live and how well the cancer responds over 12 to 36 months. The goal is to gather real-world data on the effectiveness of these treatment combinations.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this observatory could reveal which treatment combinations work best for Ph+ ALL, guiding future care.
What could go wrong
This is an observational study, not a controlled trial, so it cannot prove cause and effect. Results may not apply to all patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 100 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jan 2024

Expected to finish

Dec 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Acute Lmphoblastic Leukaemia with Philadelphia chromosome or BCR::ABL1 positive

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Male or female patients ≥ 18 years 2. Philadelphia chromosome or BCR::ABL1 positive acute lymphoblastic leukaemia 3. Treatment with the combination of BCR::ABL1 inhibitors and chemotherapy and/or corticotherapy and/or a monoclonal antibody Exclusion Criteria: 1. Patients deceded and having previously refused data collection 2. Not included in a prospective clinical trial

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Acute lymphoblastic leukemia are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

acute lymphoblastic leukemia leukemia, acute lymphocytic, susceptibility to, 1 Precursor Cell Lymphoblastic Leukemia-Lymphoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Acute lymphoblastic leukemia

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    23 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • CH Le Mans

    RECRUITING

    Le Mans, France

  • CH St Etienne

    NOT_YET_RECRUITING

    Saint-Etienne, France

  • CH Versailles

    RECRUITING

    Le Chesnay, France

  • CH de Lyon

    NOT_YET_RECRUITING

    Pierre-Bénite, France

  • CH de la cote basque

    NOT_YET_RECRUITING

    Bayonne, France

  • CHRU de Nancy

    NOT_YET_RECRUITING

    Nancy, France

  • CHU Angers

    NOT_YET_RECRUITING

    Angers, France

  • CHU Bordeaux

    RECRUITING

    Bordeaux, France

  • CHU Sud Réunion

    NOT_YET_RECRUITING

    La Réunion, France

  • CHU clermont ferrand

    RECRUITING

    Clermont-Ferrand, France

  • CHU de grenoble

    NOT_YET_RECRUITING

    Grenoble, France

  • Centre Antoine Lacassagne

    NOT_YET_RECRUITING

    Nice, 06189, France

  • Centre Hospitalier sud francilien

    RECRUITING

    Corbeil-Essonnes, France

  • Chu de Lille

    NOT_YET_RECRUITING

    Lille, France

  • Groupe hospitalier sud

    NOT_YET_RECRUITING

    Amiens, France

  • Hopital Cochin

    NOT_YET_RECRUITING

    Paris, France

  • Hopital Militaire Percy

    NOT_YET_RECRUITING

    Clamart, France

  • Hopital St Louis

    RECRUITING

    Paris, France

  • Hopital de Purpan

    NOT_YET_RECRUITING

    Toulouse, France

  • Hopital de la conception

    NOT_YET_RECRUITING

    Marseille, France

  • Hopital necker

    RECRUITING

    Paris, France

  • ICANS

    NOT_YET_RECRUITING

    Strasbourg, France

  • Institut Paoli Calmettes

    NOT_YET_RECRUITING

    Marseille, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.